Archives
-
IEM-1925 Targets Soman-Induced Status Epilepticus
2026-08-16
The 2026 NeuroToxicology study evaluates IEM-1925, a dual AMPA/NMDA glutamate receptor antagonist, in a rat model of soman-induced status epilepticus. Its combined antiseizure, neuroprotective, and cognitive benefits suggest that sustained glutamatergic signaling is an important therapeutic target after organophosphorus nerve-agent exposure, while also defining important limits for translation to human treatment.
-
DOTAP Workflows for Targeted Gene Delivery
2026-08-15
Learn how to use DOTAP for reproducible DNA, RNA, and antisense oligonucleotide delivery, from complex formation through functional readouts. The workflow also shows how DOTAP-based screening can inform lipid nanoparticle optimization and targeted glaucoma research without conflating a practical formulation screen with a validated therapeutic product.
-
iPSC Prescreening for Ultrarare Disease Trials
2026-08-14
Sequiera et al. developed a patient-specific induced pluripotent stem cell platform to prescreen therapies for an 18-year-old patient with Leigh-like syndrome and poorly characterized ECHS1 variants. The platform supported drug selection before clinical use and was associated with a shift toward a healthier metabolic profile after three years of treatment, while also illustrating the limits of extrapolating from more common mutations.
-
Targeted EPO mRNA Nanoparticles for Spinal Cord Repair
2026-08-14
A 2026 Materials Today Bio study developed mannose-modified lipid nanoparticles to deliver erythropoietin mRNA to CD206-enriched inflammatory macrophages and microglia after spinal cord injury. The platform produced localized EPO expression, reduced neuroinflammation and ferroptosis-related damage, and improved motor recovery in mice, while also illustrating the translational challenges of targeted mRNA delivery.
-
Taltirelin Acetate: From Mechanism to Translation
2026-08-13
Taltirelin acetate offers translational researchers a long-acting TRH analog for connecting receptor pharmacology with dopaminergic neuroprotection, airway motor control, itch biology, and formulation research. This article outlines evidence, assay strategy, competitive differentiation, and the limits that should shape next-generation studies.
-
D-Luciferin (potassium salt) for Reliable Assays
2026-08-13
Learn how D-Luciferin (potassium salt), SKU C3654, supports better-controlled luciferase reporter, ATP, viability, and in vivo imaging workflows. This scenario-based guide covers formulation compatibility, preparation, storage, interpretation, and practical vendor selection.
-
Thiazovivin: Practical ROCK Inhibitor Workflow Guide
2026-08-12
Thiazovivin (SKU A5506) is a ROCK inhibitor used to support fibroblast reprogramming and improve human embryonic stem cell survival after trypsinization. This guide covers formulation, handling, controls, and troubleshooting while clarifying that working concentrations, exposure times, and clinical applications must be established experimentally.
-
Iptacopan (LNP023) Complement Research Workflows
2026-08-12
Build reproducible alternative-pathway experiments with Iptacopan (LNP023), from serum C3bBb inhibition and complement-mediated hemolysis assays to PNH and complement disease models. This workflow pairs pathway-selective pharmacology with continuous dose-response analysis, orthogonal endpoints, and practical troubleshooting.
-
Omeprazole A2845: Research Protocol Guide
2026-08-11
Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research and related antiulcer assay development. This guide covers solvent handling, assay setup, and QC for in vitro or preclinical workflows; it is not evidence of clinical efficacy and is not for diagnostic or medical use.
-
Sodium Nitroprusside as a Vascular Causal Probe
2026-08-11
Sodium Nitroprusside is more than a vasodilator assay reagent: it can function as a mechanistic probe for separating vascular nitric oxide signaling from sex-dependent blood-pressure regulation. This article translates mouse hypertension findings into a rigorous ex vivo experimental framework.
-
QNZ (EVP4593) for NF-κB Research Workflows
2026-08-10
QNZ (EVP4593) provides a nanomolar starting point for linking NF-κB reporter assays with TNF-α, inflammation, and Huntington’s disease research. This workflow-focused guide combines practical compound handling with orthogonal validation and a metabolomics-inspired strategy for studying complex biological samples.
-
Anti Reverse Cap Analog (ARCA) Guide
2026-08-09
Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, is an orientation-selective Cap 0 analog for co-transcriptional synthetic mRNA capping. Supplier information reports approximately twofold higher translation than conventional m7G cap analogs under its stated in vitro transcription workflow.
-
SM-102: From LNP Component to Translational Strategy
2026-08-08
A mechanistic and translational analysis of SM-102 for mRNA delivery, integrating ionizable-lipid biology, machine-learning evidence, formulation strategy, and practical development guidance.
-
Z-VAD-FMK as a Causal Probe of Cell Death
2026-08-07
Z-VAD-FMK is more than a broad apoptosis inhibitor: it can function as a causal probe for determining whether drug-induced cell death depends on caspase signaling. This article connects z vad fmk pharmacology with recent EGFR functional-genomics findings to improve assay design and interpretation in cancer research.
-
Dinaciclib (SCH727965) in Cell Cycle & Tissue Boundary Resea
2026-08-07
Dinaciclib (SCH727965) offers a powerful route to dissecting cell cycle arrest and apoptosis mechanisms, with robust performance in both in vitro and in vivo models. Leveraging insights from boundary dynamics in development and cancer, this guide details practical protocols, advanced applications, and troubleshooting strategies for maximizing research with APExBIO’s Dinaciclib.